Search results for "Endocrine Gland Neoplasms"

showing 3 items of 3 documents

European disparities in malignant digestive endocrine tumours survival.

2009

The aim of this study was to report on malignant digestive endocrine tumours (MDET) prognosis in several European countries. We analysed survival data from 19 cancer registries in 12 European countries on 3,715 MDET diagnosed between 1985 and 1994. The overall 5-year survival rate was 47.5%. It was 58.1% for differentiated MDET and 8.1% for small-cell MDET (p < 0.001), 55.9% for patients under 65 and 37.0% for older patients. Survival rates for small intestinal and colorectal were higher than for the other sites. The 5-year relative survival rates were 60.3% in Northern Europe, 53.6% in Western Continental Europe, 42.5% in the UK, 37.6% in Eastern Europe (p < 0.001). Among well-differentiat…

MaleCancer Researchmedicine.medical_specialtyPathologyGlucagonomaDigestive System NeoplasmsGastroenterologydigestive endocrine tumours survivalInternal medicineEndocrine Gland NeoplasmsmedicineHumansCarcinoid tumourRegistriesSurvival rateAgedNeoplasm StagingGastrinomaRelative survivalbusiness.industryAbsolute risk reductionCancerMiddle Agedmedicine.diseasePrognosisCancer registryEuropeSurvival RateOncologyFemalebusinessInternational journal of cancer
researchProduct

ENDOCRINE TUMOURS: Calcitonin in thyroid and extra-thyroid neuroendocrine neoplasms: the two-faced Janus.

2020

An increased calcitonin serum level is suggestive of a medullary thyroid cancer (MTC), but is not pathognomonic. The possibility of false positives or other calcitonin-secreting neuroendocrine neoplasms (NENs) should be considered. Serum calcitonin levels are generally assessed by immunoradiometric and chemiluminescent assays with high sensitivity and specificity; however, slightly moderately elevated levels could be attributable to various confounding factors. Calcitonin values &gt;100 pg/mL are strongly suspicious of malignancy, whereas in patients with moderately elevated values (10–100 pg/mL) a stimulation test may be applied to improve diagnostic accuracy. Although the standard protoco…

MalediagnosisEndocrinology Diabetes and Metabolismbiomarkers; tumor; calcitonin; calcitonin gene-related peptide; carcinoma neuroendocrine; diagnosis differential; endocrine gland neoplasms; false positive reactions; female; humans; janus kinases; male; middle aged; reference values; sensitivity and specificity; thyroid neoplasmscarcinoma0302 clinical medicineEndocrinologyReference ValuehumansEndocrine Gland NeoplasmThyroidMedullary thyroid cancerGeneral MedicineFalse Positive Reactionreference valuesMiddle Agedmedicine.anatomical_structure030220 oncology & carcinogenesisFemalehormones hormone substitutes and hormone antagonistsHumanThyroid nodulesCalcitoninmedicine.medical_specialtytumordifferentialCalcitonin Gene-Related Peptide030209 endocrinology & metabolismNeuroendocrinologySensitivity and SpecificityDiagnosis Differential03 medical and health sciencesInternal medicinemedicineBiomarkers TumorneuroendocrineThyroid NeoplasmsCalcitonin Measurementbusiness.industryfalse positive reactionsbiomarkersCalcitonin secretionmedicine.diseaseCarcinoma NeuroendocrineEndocrinologyCalcitoninjanus kinasesJanus KinaseDifferential diagnosisendocrine gland neoplasmsbusiness
researchProduct

Endocrine tumours: epidemiology of malignant digestive neuroendocrine tumours.

2013

Little is known about patients with malignant digestive neuroendocrine tumours (MD-NETs). Although their incidence is increasing, MD-NETs remain a rare cancer, representing 1% of digestive cancers. Most MD-NETs are well-differentiated. MD-NET poorly differentiated carcinomas account for 20% of cases on average. Anatomical localisation of MD-NETs varied according to geographic region. Stage at diagnosis and prognosis for patients with MD-NETs in the general population are considerably worse than often reported from small hospital case series. Prognosis varies with tumour differentiation, anatomic site and histological subtype. There are significant differences in survival from MD-NETs among …

Oncologymedicine.medical_specialtyeducation.field_of_studybusiness.industryEndocrinology Diabetes and MetabolismPoorly differentiatedIncidence (epidemiology)PopulationGeneral MedicineRare cancerSmall hospitalNeuroendocrine TumorsEndocrinologyEndocrinologyInternal medicineEpidemiologyEndocrine Gland NeoplasmsmedicineEndocrine systemAnimalsHumansbusinesseducationDigestive cancerGastrointestinal NeoplasmsEuropean journal of endocrinology
researchProduct